Synopsis
Synopsis
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Abello, Naloxone
2. Curamed, Naloxon
3. Dihydride, Naloxone Hydrochloride
4. Hydrobromide, Naloxone
5. Hydrochloride Dihydride, Naloxone
6. Hydrochloride, Naloxone
7. Mrz 2593
8. Mrz 2593 Br
9. Mrz 2593-br
10. Mrz 2593br
11. Mrz-2593
12. Mrz2593
13. Nalone
14. Naloxon Curamed
15. Naloxon Ratiopharm
16. Naloxon-ratiopharm
17. Naloxone
18. Naloxone Abello
19. Naloxone Hydrobromide
20. Naloxone Hydrochloride Dihydride
21. Naloxone Hydrochloride, (5 Beta,9 Alpha,13 Alpha,14 Alpha)-isomer
22. Naloxone, (5 Beta,9 Alpha,13 Alpha,14 Alpha)-isomer
23. Narcan
24. Narcanti
1. Naloxone Hcl
2. 357-08-4
3. Narcan
4. Narcanti
5. Naloxone (hydrochloride)
6. Evzio
7. Nih 7890
8. En-15304
9. Anhydrous Naloxone Hydrochloride
10. Chebi:31892
11. F850569pqr
12. Nsc-757109
13. (-)-n-allyl-14-hydroxynordihydromorphinone Hydrochloride
14. 357-08-4 (hcl)
15. 17-allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
16. (5alpha)-17-allyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
17. (4r,4as,7ar,12bs)-3-allyl-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7ah)-one Hydrochloride
18. Nalonee
19. Mls000069540
20. Naloxonehydrochloride
21. Smr000058766
22. Unii-f850569pqr
23. Prestwick_879
24. Einecs 206-611-0
25. Mfcd00069322
26. Narcan (tn)
27. Kloxxado
28. Evzio (tn)
29. Nafoxone Hydrochloride
30. Nal-oxon Hydrochloride
31. Naloxone Hydrochloride [usan:usp:jan]
32. En 15304
33. Chembl1718
34. C19h21no4.hcl
35. Schembl41390
36. L-n-allyl-14-hydroxynordihydromorphinone Hydrochloride
37. Naloxone Hydrochloride Anhydrous
38. Dtxsid70957097
39. Hms1568g04
40. Naloxone Hydrochloride [mi]
41. Act02626
42. Naloxone Hydrochloride (jp17/usp)
43. Naloxone Hydrochloride [jan]
44. (5a)-17-allyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
45. 17-allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
46. Naloxone Hydrochloride [usan]
47. Normorphinone, N-allyl-7,8-dihydro-14-hydroxy-, Hydrochloride, (-)-
48. S3066
49. Naloxone Hydrochloride [vandf]
50. Akos024418753
51. Morphinan-6-one, 17-allyl-4,5-alpha-epoxy-3,14-dihydroxy-, Hydrochloride
52. Naloxone Hydrochloride [mart.]
53. Ccg-220111
54. Cs-1335
55. Ks-5379
56. Naloxone Hydrochloride [who-dd]
57. Nc00587
58. Nsc 757109
59. Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, Hydrochloride, (5.alpha.)-
60. Hy-17417
61. Naloxone Hydrochloride [green Book]
62. Naloxone Hydrochloride [orange Book]
63. Sw197001-3
64. Naloxone Hydrochloride [usp Monograph]
65. D01340
66. Suboxone Component Naloxone Hydrochloride
67. Targiniq Component Naloxone Hydrochloride
68. Naloxone Hydrochloride Anhydrous [who-ip]
69. Talwin Nx Component Naloxone Hydrochloride
70. 357n084
71. Naloxone Hydrochloride Component Of Suboxone
72. Naloxone Hydrochloride Component Of Targiniq
73. Sr-01000597918
74. Sr-01000737374
75. Naloxone Hydrochloride Component Of Talwin Nx
76. Sr-01000597918-1
77. Sr-01000737374-3
78. W-106655
79. Q27114711
80. Naloxoni Hydrochloridum Anhydrous [who-ip Latin]
81. (5alpha)-17-allyl-3,14-dihydroxy-4,5-epoxymorphinan-6-one Hydrochloride
82. 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one Hydrochloride
83. (17r)-17-allyl-3,14-dihydroxy-6-oxo-4,5alpha-epoxymorphinan-17-ium Chloride
84. (5?)-4,5-epoxy-3,14-dihydro-17-(2-propenyl)morphinan-6-one Hydrochloride
85. (5a)-4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-morphinan-6-one Hydrochloride
86. (5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-one Hydrochloride (1:1)
87. (5alpha,17r)-17-allyl-3,14-dihydroxy-6-oxo-4,5-epoxymorphinan-17-ium Chloride
88. 17-allyl-4,5.alpha.-epoxy-3,14-dihydroxymorphinan-6-one Hydrochloride
89. Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, Hydrochloride, (5alpha)-
90. (4r,4as,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
91. (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
92. (5alpha)-4,5-epoxy-3,14-dihydro-17-(2-pr Openyl)morphinan-6-one Hydrochloride
Molecular Weight | 363.8 g/mol |
---|---|
Molecular Formula | C19H22ClNO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 363.1237359 g/mol |
Monoisotopic Mass | 363.1237359 g/mol |
Topological Polar Surface Area | 70 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 594 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Evzio |
PubMed Health | Naloxone (Injection) |
Drug Classes | Toxicology-Antidote Agent |
Drug Label | EVZIO (naloxone hydrochloride injection, USP) is a pre-filled, single-use auto-injector. EVZIO is not made with natural rubber latex. Chemically, naloxone hydrochloride is the hydrochloride salt of 17-Allyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one h... |
Active Ingredient | Naloxone hydrochloride |
Dosage Form | Solution |
Route | Intramuscular, subcutaneous |
Strength | 0.4mg/0.4ml |
Market Status | Prescription |
Company | Kaleo |
2 of 4 | |
---|---|
Drug Name | Naloxone hydrochloride |
Drug Label | Ampul, Fliptop Vial, Opioid AntagonistProtect from light.RxNaloxone Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of naloxone hydrochloride in water for injection. Each milliliter (mL) contains 0.4 mg naloxone hydrochloride and sod... |
Active Ingredient | Naloxone hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/ml; 0.4mg/ml |
Market Status | Prescription |
Company | Hospira; Intl Medication; Mylan Institutional |
3 of 4 | |
---|---|
Drug Name | Evzio |
PubMed Health | Naloxone (Injection) |
Drug Classes | Toxicology-Antidote Agent |
Drug Label | EVZIO (naloxone hydrochloride injection, USP) is a pre-filled, single-use auto-injector. EVZIO is not made with natural rubber latex. Chemically, naloxone hydrochloride is the hydrochloride salt of 17-Allyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one h... |
Active Ingredient | Naloxone hydrochloride |
Dosage Form | Solution |
Route | Intramuscular, subcutaneous |
Strength | 0.4mg/0.4ml |
Market Status | Prescription |
Company | Kaleo |
4 of 4 | |
---|---|
Drug Name | Naloxone hydrochloride |
Drug Label | Ampul, Fliptop Vial, Opioid AntagonistProtect from light.RxNaloxone Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of naloxone hydrochloride in water for injection. Each milliliter (mL) contains 0.4 mg naloxone hydrochloride and sod... |
Active Ingredient | Naloxone hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 1mg/ml; 0.4mg/ml |
Market Status | Prescription |
Company | Hospira; Intl Medication; Mylan Institutional |
Treatment of opioid-induced constipation
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Naloxone hydrochloride prefilled injection, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Narcan-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2020
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naloxone hydrochloride prefilled injection, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites.
Product Name : Narcan-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 19, 2020
Details:
The collaboration aims to develop naloxone, a controlled substance targeting opioid receptors (mu/kappa/delta), to address opioid overdose.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Narcan-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: The Naloxone Project
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 23, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : The Naloxone Project
Deal Size : Undisclosed
Deal Type : Collaboration
Padagis, The Naloxone Project Partner to Expand Nationwide Naloxone Access
Details : The collaboration aims to develop naloxone, a controlled substance targeting opioid receptors (mu/kappa/delta), to address opioid overdose.
Product Name : Narcan-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 23, 2025
Details:
Naloxone is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Johnson County ClinTrials
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Johnson County ClinTrials
Deal Size : Inapplicable
Deal Type : Inapplicable
Proof of Concept (PoC) Evaluation of Naloxone Unique Intramuscular (IM) Injection
Details : Naloxone is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2025
Details:
SOOPR (naloxone) is an opioid receptor antagonist indicated in the reversal of opioid overdoses.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: SOOPR
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 20, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Elysium Completes FDA Pre-IND For Tech To Combat Fentanyl Overdose
Details : SOOPR (naloxone) is an opioid receptor antagonist indicated in the reversal of opioid overdoses.
Product Name : SOOPR
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2025
Details:
Kloxxado delivers 8 mg of naloxone hydrochloride, an opioid antagonist, approved as a ready to use nasal spray to reverse the effects of opioid overdose.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Kloxxado
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Details : Kloxxado delivers 8 mg of naloxone hydrochloride, an opioid antagonist, approved as a ready to use nasal spray to reverse the effects of opioid overdose.
Product Name : Kloxxado
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 20, 2025
Details:
Polyrizon is advancing intranasal naloxone, which is currently being evaluated for the treatment of patients suffering from opioid overdose.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyrizon Begins Preclinical Trials for Intranasal Naloxone
Details : Polyrizon is advancing intranasal naloxone, which is currently being evaluated for the treatment of patients suffering from opioid overdose.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 13, 2025
Details:
Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyrizon Begins Preclinical Intranasal Naloxone Study for Opioid Overdose Therapy
Details : Naloxone is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 10, 2025
Details:
Under the agreement, Scienture will own the NDA for Rezenopy (Naloxone HCl) in its name and be responsible for the sales, marketing and distribution of the product in the US.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Rezenopy
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Scienture
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 06, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Scienture
Deal Size : Undisclosed
Deal Type : Agreement
Scienture, Kindeva Launch REZENOPY® for Opioid Overdose Treatment
Details : Under the agreement, Scienture will own the NDA for Rezenopy (Naloxone HCl) in its name and be responsible for the sales, marketing and distribution of the product in the US.
Product Name : Rezenopy
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 06, 2025
Details:
Under the terms of the agreement, Emergent will be responsible for the distribution of Kloxxado (Naloxone HCl). It is being indicated for the treatment of known or suspected opioid overdose.
Lead Product(s): Naloxone Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Kloxxado
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Emergent BioSolutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2025
Lead Product(s) : Naloxone Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Emergent BioSolutions
Deal Size : Undisclosed
Deal Type : Agreement
Emergent BioSolutions Gains Exclusive Rights to KLOXXADO® Nasal Spray
Details : Under the terms of the agreement, Emergent will be responsible for the distribution of Kloxxado (Naloxone HCl). It is being indicated for the treatment of known or suspected opioid overdose.
Product Name : Kloxxado
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 14, 2025
Details:
INDV-6001 is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Related Disorders.
Lead Product(s): INDV-6001,Buprenorphine,Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2024
Lead Product(s) : INDV-6001,Buprenorphine,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
INDV-6001 Multiple-Dose Pharmacokinetic Study
Details : INDV-6001 is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Related Disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 29, 2024
CAS Number : 115-37-7
End Use API : Naloxone Hydrochloride
About The Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class...
CAS Number : 57664-96-7
End Use API : Naloxone Hydrochloride
About The Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class...
CAS Number : 52446-25-0
End Use API : Naloxone Hydrochloride
About The Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class...
2,2,2-Trichloroethyl chloroformate
CAS Number : 17341-93-4
End Use API : Naloxone Hydrochloride
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
CAS Number : 33522-95-1
End Use API : Naloxone Hydrochloride
About The Company : Founded in 1979, Noramco specializes in the development and manufacturing of APIs for both opioid and non-opioid products. With expertise in controlled substanc...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
25
PharmaCompass offers a list of Naloxone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naloxone Hydrochloride manufacturer or Naloxone Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naloxone Hydrochloride manufacturer or Naloxone Hydrochloride supplier.
PharmaCompass also assists you with knowing the Naloxone Hydrochloride API Price utilized in the formulation of products. Naloxone Hydrochloride API Price is not always fixed or binding as the Naloxone Hydrochloride Price is obtained through a variety of data sources. The Naloxone Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Endo Brand of Naloxone Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Endo Brand of Naloxone Hydrochloride, including repackagers and relabelers. The FDA regulates Endo Brand of Naloxone Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Endo Brand of Naloxone Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Endo Brand of Naloxone Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Endo Brand of Naloxone Hydrochloride supplier is an individual or a company that provides Endo Brand of Naloxone Hydrochloride active pharmaceutical ingredient (API) or Endo Brand of Naloxone Hydrochloride finished formulations upon request. The Endo Brand of Naloxone Hydrochloride suppliers may include Endo Brand of Naloxone Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Endo Brand of Naloxone Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Endo Brand of Naloxone Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Endo Brand of Naloxone Hydrochloride DMFs exist exist since differing nations have different regulations, such as Endo Brand of Naloxone Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Endo Brand of Naloxone Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Endo Brand of Naloxone Hydrochloride USDMF includes data on Endo Brand of Naloxone Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Endo Brand of Naloxone Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Endo Brand of Naloxone Hydrochloride Drug Master File in Japan (Endo Brand of Naloxone Hydrochloride JDMF) empowers Endo Brand of Naloxone Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Endo Brand of Naloxone Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Endo Brand of Naloxone Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Endo Brand of Naloxone Hydrochloride Drug Master File in Korea (Endo Brand of Naloxone Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Endo Brand of Naloxone Hydrochloride. The MFDS reviews the Endo Brand of Naloxone Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Endo Brand of Naloxone Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Endo Brand of Naloxone Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Endo Brand of Naloxone Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with KDMF on PharmaCompass.
A Endo Brand of Naloxone Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Endo Brand of Naloxone Hydrochloride Certificate of Suitability (COS). The purpose of a Endo Brand of Naloxone Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Endo Brand of Naloxone Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Endo Brand of Naloxone Hydrochloride to their clients by showing that a Endo Brand of Naloxone Hydrochloride CEP has been issued for it. The manufacturer submits a Endo Brand of Naloxone Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Endo Brand of Naloxone Hydrochloride CEP holder for the record. Additionally, the data presented in the Endo Brand of Naloxone Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Endo Brand of Naloxone Hydrochloride DMF.
A Endo Brand of Naloxone Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Endo Brand of Naloxone Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Endo Brand of Naloxone Hydrochloride written confirmation (Endo Brand of Naloxone Hydrochloride WC) is an official document issued by a regulatory agency to a Endo Brand of Naloxone Hydrochloride manufacturer, verifying that the manufacturing facility of a Endo Brand of Naloxone Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Endo Brand of Naloxone Hydrochloride APIs or Endo Brand of Naloxone Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Endo Brand of Naloxone Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Endo Brand of Naloxone Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Endo Brand of Naloxone Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Endo Brand of Naloxone Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Endo Brand of Naloxone Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Endo Brand of Naloxone Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Endo Brand of Naloxone Hydrochloride suppliers with NDC on PharmaCompass.
Endo Brand of Naloxone Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Endo Brand of Naloxone Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Endo Brand of Naloxone Hydrochloride GMP manufacturer or Endo Brand of Naloxone Hydrochloride GMP API supplier for your needs.
A Endo Brand of Naloxone Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Endo Brand of Naloxone Hydrochloride's compliance with Endo Brand of Naloxone Hydrochloride specifications and serves as a tool for batch-level quality control.
Endo Brand of Naloxone Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Endo Brand of Naloxone Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Endo Brand of Naloxone Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Endo Brand of Naloxone Hydrochloride EP), Endo Brand of Naloxone Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Endo Brand of Naloxone Hydrochloride USP).